Koss Olinger Consulting LLC acquired a new position in shares of Corteva, Inc. (NYSE:CTVA - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,846 shares of the company's stock, valued at approximately $618,000.
Several other institutional investors have also recently added to or reduced their stakes in the company. Oak Thistle LLC acquired a new stake in shares of Corteva during the fourth quarter worth $1,514,000. Charles Schwab Investment Management Inc. lifted its position in Corteva by 1.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 4,523,996 shares of the company's stock worth $265,966,000 after buying an additional 66,052 shares during the period. Van ECK Associates Corp boosted its stake in Corteva by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 9,428,206 shares of the company's stock worth $537,031,000 after buying an additional 525,531 shares during the last quarter. Swedbank AB grew its holdings in Corteva by 51.9% in the 4th quarter. Swedbank AB now owns 695,641 shares of the company's stock valued at $39,624,000 after buying an additional 237,764 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Corteva by 755.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 552,769 shares of the company's stock valued at $31,486,000 after acquiring an additional 488,181 shares during the last quarter. Institutional investors and hedge funds own 81.54% of the company's stock.
Insider Transactions at Corteva
In related news, insider Brian Titus sold 26,560 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $63.74, for a total transaction of $1,692,934.40. Following the sale, the insider now owns 11,347 shares of the company's stock, valued at $723,257.78. The trade was a 70.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.20% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on CTVA shares. Oppenheimer boosted their target price on shares of Corteva from $70.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, February 7th. UBS Group lowered their price objective on shares of Corteva from $74.00 to $73.00 and set a "buy" rating for the company in a research note on Friday, January 10th. Royal Bank of Canada upped their price objective on Corteva from $72.00 to $73.00 and gave the stock an "outperform" rating in a report on Friday, February 7th. KeyCorp lifted their target price on Corteva from $68.00 to $70.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Finally, Citigroup upped their price target on Corteva from $69.00 to $74.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Corteva currently has an average rating of "Moderate Buy" and a consensus target price of $68.00.
View Our Latest Stock Report on CTVA
Corteva Stock Performance
Shares of NYSE:CTVA traded down $0.13 during trading on Friday, reaching $61.70. 6,880,464 shares of the company's stock traded hands, compared to its average volume of 3,049,251. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.45 and a quick ratio of 0.93. The company has a 50 day moving average of $62.44 and a 200-day moving average of $59.87. Corteva, Inc. has a 12 month low of $50.01 and a 12 month high of $66.24. The stock has a market capitalization of $42.30 billion, a P/E ratio of 47.83, a price-to-earnings-growth ratio of 1.68 and a beta of 0.79.
Corteva (NYSE:CTVA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.34 by ($0.02). Corteva had a return on equity of 7.19% and a net margin of 5.36%. On average, equities analysts expect that Corteva, Inc. will post 2.96 EPS for the current year.
Corteva Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, March 17th. Shareholders of record on Monday, March 3rd were paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date of this dividend was Monday, March 3rd. Corteva's payout ratio is 52.71%.
Corteva Company Profile
(
Free Report)
Corteva, Inc operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics.
Featured Articles

Before you consider Corteva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corteva wasn't on the list.
While Corteva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.